Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

IMMUTEP LIMITED Capital/Financing Update 2007

Nov 21, 2007

65122_rns_2007-11-21_bb712056-1fc1-4052-a395-d699762ceacb.pdf

Capital/Financing Update

Open in viewer

Opens in your device viewer

ABN 90 009 237 889

==> picture [193 x 51] intentionally omitted <==

22[nd] November 2007

Company Announcements Office Australian Securities Exchange Level 45, Rialto South Tower 525 Collins Street Melbourne VIC 3000

Dear Sir/Madam,

Rights Issue Closed

The Directors are pleased to announce that the Company’s 1:2 Non-Renounceable Rights Issue is closed with over 15% of the entitlement taken up.

The Company has received total acceptances for listed shares issued under the Rights Issue of 15,170,970 at an issue price of $0.02 cents per share raising a total of $303,419 (before costs).

Notice of the shortfall of 83,855,668 shares has been given to the underwriter, RM Capital Pty Ltd.

Yours faithfully

==> picture [172 x 73] intentionally omitted <==

Robert Kleine Company Secretary

Prima BioMed Limited , Suite 1, 1233 High Street, Armadale, VIC 3143 AUSTRALIA Ph: +61 (0)3 9854 5700 Fax: +61 (0)3 9822 7735 www.primabiomed.com.au